Greg Verdine, LifeMine
Rick Klausner fronts cash for his fungus outfit LifeMine and brings on Nobel laureate to further push cancer discovery
More than three years after launching with a $55 million Series A, fungus player LifeMine Therapeutics is back with a trifecta of new goodies …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.